Crinetics Pharmaceuticals, Inc. (CRNX)
84.95
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
Crinetics Pharmaceuticals Research and Development Expense (Quarterly) : 99.38M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 99.38M |
| March 31, 2026 | 98.92M |
| December 31, 2025 | 84.06M |
| September 30, 2025 | 89.45M |
| June 30, 2025 | 79.34M |
| March 31, 2025 | 75.32M |
| December 31, 2024 | 65.78M |
| September 30, 2024 | 61.14M |
| June 30, 2024 | 57.59M |
| March 31, 2024 | 52.87M |
| December 31, 2023 | 45.32M |
| September 30, 2023 | 43.57M |
| June 30, 2023 | 40.36M |
| March 31, 2023 | 38.18M |
| December 31, 2022 | 36.71M |
| September 30, 2022 | 31.74M |
| June 30, 2022 | 32.78M |
| March 31, 2022 | 28.01M |
| December 31, 2021 | 24.37M |
| Date | Value |
|---|---|
| September 30, 2021 | 21.35M |
| June 30, 2021 | 20.26M |
| March 31, 2021 | 17.36M |
| December 31, 2020 | 16.60M |
| September 30, 2020 | 13.46M |
| June 30, 2020 | 12.36M |
| March 31, 2020 | 13.63M |
| December 31, 2019 | 12.14M |
| September 30, 2019 | 11.82M |
| June 30, 2019 | 10.28M |
| March 31, 2019 | 7.255M |
| December 31, 2018 | 7.651M |
| September 30, 2018 | 6.886M |
| June 30, 2018 | 5.222M |
| March 31, 2018 | 4.72M |
| December 31, 2017 | 2.562M |
| September 30, 2017 | 2.523M |
| June 30, 2017 | 2.083M |
| March 31, 2017 | 2.065M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Johnson & Johnson | 3.603B |
| Eli Lilly & Co. | 3.819B |
| Bristol Myers Squibb Co. | 2.316B |
| Corcept Therapeutics, Inc. | 53.89M |